Please login to the form below

Not currently logged in
Email:
Password:

multidrug resistant infections

This page shows the latest multidrug resistant infections news and features for those working in and with pharma, biotech and healthcare.

Pfizer launches antibiotic resistance surveillance website

Pfizer launches antibiotic resistance surveillance website

Dr Freda Lewis-Hall, Pfizer’s chief medical officer, said: “An important aspect for physicians when treating patients is knowledge; knowledge of where certain resistant bacterial infections tend to occur and ... Meanwhile, Pfizer’s new antibiotic

Latest news

  • Pfizer launches new antibiotic Zavicefta in UK and Germany Pfizer launches new antibiotic Zavicefta in UK and Germany

    Biopharmaceutical company Pfizer releases MDR antibiotic. Pfizer's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been launched in the UK and Germany, its first EU markets. ... One of the key roles for the new product is in the

  • AZ gets EU green light for new antibiotic Zavicefta AZ gets EU green light for new antibiotic Zavicefta

    EMA approves combination drug for treatment of multidrug resistant infections. AstraZeneca's new antibiotic for multidrug resistant (MDR) infections - Zavicefta - has been approved for marketing in the EU. ... Some CRE infections are resistant to all

  • Merck starts pivotal trials of new antibiotic combination Merck starts pivotal trials of new antibiotic combination

    Beta-lactamase inhibitor relebactam is a welcome addition to the late-stage antibiotics pipeline, which remains fairly sparse despite high levels of concern worldwide about multidrug resistant (MDR) infections. ... imipenem), a broad-spectrum carbapenem

  • CHMP backs AZ's 'superbug' antibiotic product CHMP backs AZ's 'superbug' antibiotic product

    Zavicefta recommended for European approval. AstraZeneca is months away from introducing Zavicefta, its new antibiotic product for multidrug resistant (MDR) infections, in the EU. ... Some CRE infections are resistant to all known antibiotics and

  • Roche drops superbug partnership with Polyphor Roche drops superbug partnership with Polyphor

    But adds inflammation research agreement with Proximagen.  . Roche has opted to discontinue an alliance with Swiss biopharma company Polyphor to develop antibiotics for resistant infections. ... Roche's decision to drop the programme comes at a time of

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics